No Data
No Data
Huadong Medicine (000963.SZ): HDM1002 is currently in Phase II clinical trials in China.
Huadong Medicine (000963.SZ) stated on the investor interaction platform on July 5th that the company will choose the overseas clinical development path according to the project situation in the future. HDM1002 is currently in phase II clinical research in China.
Huadong Medicine (000963.SZ): Baoling Health has products such as "Good Elements PQQ Collagen Peptide Drink".
On July 5th, Gelunhui reported that Huadong Medicine (000963.SZ) stated on their investor interaction platform that their subsidiary, Bailin Health, has products such as 'Shanyao PQQ Collagen Peptide Drink.'
Huadong Medicine's Unit Gets US FDA's Nod to Trial Tumor Drug
Huadong Medicine's (SHE:000963) unit, Hangzhou Sino-US Huadong Pharmaceutical, will conduct Phase I clinical trials on HDM2005 for injection in the US after receiving the approval of the country's Foo
Investors Don't See Light At End Of Huadong Medicine Co., Ltd's (SZSE:000963) Tunnel
Huadong Medicine Co., Ltd's (SZSE:000963) price-to-earnings (or "P/E") ratio of 16.7x might make it look like a buy right now compared to the market in China, where around half of the companies have P
Huadong Medicine (000963.SZ): HDM2005, the injectable drug used in China and the United States, has obtained the approval of FDA's new drug clinical trial.
On July 1st, Gelunhui reported that Huadong Medicine (000963.SZ) announced that its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (hereinafter referred to as "Zhongmei Huadong"), received a notification from the U.S. Food and Drug Administration (FDA) that the clinical trial application for injection HDM2005 drugs declared by Zhongmei Huadong has been approved by the FDA and can conduct phase I clinical trials in the United States. Injected HDM2005 is a type 1 new biopharmaceutical with global intellectual property rights developed by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. It is a targeted receptor tyrosine.
Express News | Huadong Medicine - Hdm1002 Phase Ib Trial Shows Significant Weight Loss in 100Mg or Higher Dose Group
No Data